The loss of tyrosinase, the key enzyme in melanin synthesis, has been implicated in the dedifferentiation of malignant melanocytes. The presence of tyrosinase transcripts and antigenic peptides in melanoma tumors prompted us to investigate whether the basis for the loss of the enzyme was proteolytic degradation. Toward this aim, we followed the kinetics of synthesis, degradation, processing, chaperone binding, inhibitor sensitivity, and subcellular localization of tyrosinase in normal and malignant melanocytes. We found that, in amelanotic melanoma cell lines, tyrosinase failed to reach the melanosome, the organelle for melanin synthesis, because it was retained in the endoplasmic reticulum (ER) and then degraded. Tyrosinase appeared mostly as a 70-kDa core-glycosylated, endoglycosidase H-sensitive, immature form bound to the ER chaperone calnexin and had a life-span of only 25% of normal. Maturation and transit from the ER to the Golgi compartment was facilitated by lowering the temperature of incubation to 31°C. Several proteasome inhibitors caused the accumulation of an Ϸ60-kDa tyrosinase doublet that was more prominent in malignant than in normal melanocytes and promoted, to various degrees, the maturation of tyrosinase in melanoma cells and the translocation of the enzyme to melanosomes. The appearance of ubiquitinated tyrosinase after treatment of normal melanocytes with N-acetyl-L-leucinyl-L-leucinal-L-norleucinal reinforced our notion that some tyrosinase is normally degraded by proteasomes. Proteolysis of tyrosinase by proteasomes is consistent with the production of antigenic tyrosinase peptides that are presented to the immune system by major histocompatibility complex class I molecules.
Loss of pigmentation is observed in human melanomas in situ and in metastatic melanoma cells established in culture. The several studies designed to elucidate the basis for this phenotype have been focused on tyrosinase, the key enzyme of melanogenesis. In those in which both protein and mRNA levels were examined, a posttranscriptional regulation was implicated because, despite low or undetectable tyrosinase protein levels, tyrosinase mRNA was detected easily (refs. 1-4 and unpublished results). The latter was found in solid tumors, in cells in culture, and in blood-borne melanoma cells (5) (6) (7) . The possibility that melanocyte-specific proteins were synthesized but later degraded was supported by the numerous reports identifying peptides derived from such melanogenic proteins as tyrosinase, TRP1͞gp75, and gp100͞Pmel 17 that serve as tumor antigens recognized by T cells of melanoma patients (see, for example, refs. 8 and 9 reviewed in ref. 10) .
Tyrosinase (70-80 kDa) is a type I membrane glycoprotein whose cDNA predicts a peptide of Ϸ58 kDa, a 28-amino acid cytosolic tail, and five putative N-glycosylation sites (refs. 2 and 11 and for review see refs. 12 and 13). Like other membrane glycoproteins, tyrosinase is processed in the endoplasmic reticulum (ER) by resident chaperones and enzymes (14, 15) . Reductions in melanoma tyrosinase levels could be mediated by the quality control system of the ER because selective retention in the ER and subsequent degradation by the proteasome complex occurs in several genetic diseases. An example is the cystic fibrosis transmembrane conductance regulator in which a mutation blocks proper processing and transport to the cell membrane (refs. 16 and 17 and see reviews in refs. 18 and 19) . Proteasomal proteolysis is implicated also in the generation of peptides for presentation by major histocompatibility complex class I molecules (20, 21) , so we set out to examine whether tyrosinase in amelanotic melanoma cells was also subject to degradation by proteasomes.
MA, and by Calbiochem) was dissolved in H 2 O and applied at 10 or 20 g͞ml for 3 or 4 h as described (20, 25) .
Western Analysis, Immunoprecipitation, and Antibodies. CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate) lysis buffer [2% CHAPS in 50 mM Hepes and 200 mM NaCl, pH 7.5, containing protease inhibitors (26) ] was used to lyse cells and to wash bead-bound precipitated material. Western blot analyses of whole cell lysates (25 or 40 g protein͞lane), immunoprecipitated products, or affinity purified glycoproteins were performed following standard procedures (27) or the manufacturer's instructions (Sigma). Equal protein loading was verified by staining the gels with Coomassie brilliant blue after transfer of the proteins to membranes.
Tyrosinase was detected with rabbit polyclonal anti-tyrosinase antibodies (1, 3), anti-peptide rabbit antiserum PEP7 (28), or mouse mAb T311 (29) (as indicated in the legends), with similar results. Other immunological reagents were anti-calnexin mouse mAb AF8 (30) or anti-calnexin rabbit antiserum (31) , rabbit polyclonal antibodies to full length calreticulin (32) (PA3-900, ABR; Affinity Bioreagents, Golden, CO), mAb to the cyclindependent kinase inhibitor p21
WAF1͞Cip1 (anti Cip1; Transduction Laboratories, Lexington, KY), and mAb 4F3 to ubiquitin (33) . The latter was used after the blotted membrane was autoclaved for 15 min in distilled water to denature ubiquitin.
Metabolic Labeling. Pulse-chase experiments were performed and analyzed with slight modifications as described (1) . In brief, cells were pulse-labeled (15 min) with [ 35 S]Protein Labeling Mix (EXPRE 35 S 35 S, 0.8 mCi͞ml; DuPont͞NEN) in methionine͞ cysteine-free medium and either collected immediately or after a chase incubation in nonradioactive medium for the indicated time. Cell extracts (2-10 ϫ 10 7 cpm in trichloroacetic acidprecipitable material) were treated with control rabbit antibodies to remove nonspecific binding proteins and then subjected to immunoprecipitation with a mixture of polyclonal and monoclonal anti-tyrosinase antibodies. The bound immune complexes (Protein A͞G-Plus-Agarose beads, Santa Cruz Biotechnology) were washed extensively (Ϸ10 times) for 2 days with RIPA buffer (0.15 mM NaCl͞0.05 mM Tris⅐HCl, pH 7.2͞1% Triton X-100͞1% sodium deoxycholate͞0.1% SDS) (27) on a shaking platform, eluted, and subjected to SDS͞PAGE fractionation and autoradiography (4-6 days). Densities of radioactive tyrosinase bands on the x-ray films were estimated using a Molecular Dynamics image analyzer.
Carbohydrate Cleavage. Cell lysates (300-500 g of protein in Ϸ100 l of CHAPS lysis buffer) were incubated with 50-70 l of wheat germ agglutinin bound to beads (Sigma) on ice, shaking, for 1 day. Bead-bound proteins were hydrolyzed with endoglycosidase H (Endo H), or N-glycosidase F according to the manufacturer's instruction (Boehringer Mannheim). Reaction products were subjected to Western analysis with antityrosinase antibodies.
Tyrosinase Activity and Subcellular Localization. Tyrosinase assays were performed as described (1) . One unit of Immunoprecipitation reaction mixtures contained 3.6 ϫ 10 7 cpm in trichloroacetic acid-precipitable material (lanes 1-11) or 2 ϫ 10 7 cpm (lanes 12-15). X-ray films were exposed to the dried gels for 4 days. (C) Band densities as a function of chase time. Data were derived from the x-ray films presented in B, scanned with a Molecular Dynamics Image Analyzer. E, Lanes 5-8; å, lanes 9-11; and s, lanes 12-14, normalized to compensate for lower specific radioactivity in labeled proteins.
tyrosinase was defined as the amount of enzyme that catalyzed the oxidation of 1 mmol of tyrosine in 1 min. Electron microscopic localization of tyrosinase activity by the dihydroxy L-phenyl alanine reaction was performed as described (34) .
RESULTS AND DISCUSSION
Tyrosinase in Amelanotic Melanoma Cells Is a 70-kDa Doublet Glycoprotein That Is Rapidly Degraded. Steady-state levels of tyrosinase were consistently less abundant in melanoma cells than in normal melanocytes (Fig. 1 A) . Furthermore, melanoma tyrosinase appeared as a distinct Ϸ70-kDa doublet rather than the 70-to 84-kDa range band of normal tyrosinase ( Fig. 1 A, lanes 12-14) . Similar data were obtained by probing whole cell lysates (Fig. 4 B The 70-kDa doublet in melanoma cells ( Fig. 1 A, lanes 12-14) could represent premature forms of tyrosinase or degradation products of the slower migrating species. A pulsechase experiment distinguished between these possibilities and established the kinetics of tyrosinase processing. In normal melanocytes, newly synthesized tyrosinase appeared as a 70-kDa doublet (Figs. 1B, lanes 1 and 5, 3C, lane 6, and 5A, lanes 1 and 13) that was slowly processed to the larger species (Figs. 1B, lanes 2-4 and 6-8 and 5A, lanes 2-3). However, even after 3 hours of chase, some of the faster migrating unprocessed species persisted (Figs. 1B, lane 6, and 3C, lane 7). The enzyme was relatively stable, with a half-life of more than 12 h as determined by the slope of decay (Figs. 1B, lanes 5-8, and C) .
Similar analyses in melanoma cells revealed very little processing of tyrosinase to the 80-kDa forms (Figs. 1B, lanes 10 and 13, 3C, lanes 1-3, and 5A, lanes [14] [15] [16] [17] . Furthermore, tyrosinase levels were found to rapidly decline with a half-life of Ϸ3 h (Fig. 1B, lanes 9-14, and C) . Rates of tyrosinase synthesis in melanoma cells relative to normal melanocytes varied. In two melanoma cell lines (YUGEN8 and 501 mel), rates were reduced slightly and in two others (YUSAC2 and YUSIT1) markedly (to one-half or one-third of normal) (Figs. 1 B and C, 3C, and 5A, time zero). These results indicate that, in some melanoma cell lines, the low levels of tyrosinase can be attributed to low rates of synthesis, but in all melanoma cell lines the maturation of tyrosinase was retarded.
The Immature Forms of Melanoma Tyrosinase Are ER Glycoforms. In normal and malignant melanocytes, the 70-kDa doublet corresponded to an Endo H-sensitive glycoform ( Fig.  2A) . The Ϸ80-kDa tyrosinase present only in normal melanocytes was Endo H-resistant (Fig. 2 A) . In both cell types, the Ϸ70-kDa doublet was digested to an Ϸ60-kDa protein, an expected size after cleavage of N-linked glycans from the five putative glycosylation sites but preservation of a single GlcNAc (N-acetyl glucosamine) residue (35) . Treating cells with reducing agents DTT or 2-mercaptoethanol, which expose free thiol groups in proteins and cause retention in the ER (36, 37) , caused the accumulation of a Ϸ70-kDa Endo H-sensitive tyrosinase doublet in normal human melanocytes but not in melanoma cells (Fig.  2B ). This finding indicates that disulfide linkages modulate the normal exit of tyrosinase from the ER and confirms that the lower molecular weight species of tyrosinase is consistent with an ER-localized, high mannose glycoform (14) .
Calnexin and calreticulin are homologous chaperones that have been proposed to play a role in the retention of misfolded proteins in the ER (38) . They associate with monoglucosylated glycoproteins localized in the ER (39) . Their complex formation with tyrosinase was revealed by coimmunoprecipitation (Fig. 2C) . Calnexin was associated with the 70-kDa tyrosinase isoform in all cell lines (Fig. 2C, lanes 1-5) . Calreticulin, by contrast, was associated with the 70-kDa doublet only in normal melanocytes (Fig. 2C, compare lane 6 with lanes 7-10) . The 70-kDa doublet from melanoma cells was, however, able to bind a bacterially produced, purified, recombinant glutathione S-transferasecalreticulin fusion protein in vitro (data not shown). The in vitro binding to calreticulin suggested that tyrosinase possessed the necessary monoglucosylated glycans required also for calreticulin binding in vivo (40) but that the microenvironment within the ER did not permit this association.
We ruled out the possibilities that the failure of tyrosinase to exit from the ER was caused by (i) its association with two cytosolic heat shock proteins, hsp70͞72 and hsp90, known to influence protein folding and (ii) a deficiency or surplus of ER chaperones or enzymes, including calnexin, calreticulin, GRP94, BiP, PDI, ERp72, ER-60, or UDP-Glc:glycoprotein glucosyltransferase (data not shown). Our studies also have indicated that tyrosinase does not form disulfide-linked aggregates because high molecular weight complexes were not observed upon resolution by nonreducing SDS͞PAGE (data not shown). Taken together, the data suggest that tyrosinase in amelanotic melanoma cells is misfolded and thus cannot reach destinations beyond the ER.
Recovery of Mature Tyrosinase After Culturing Melanoma Cells at Reduced Temperature. Decreases in temperature have been shown to relieve ER retention of misfolded mutant glycoproteins (41, 42) . To confirm that melanoma tyrosinase was in an immature conformation, we assessed the effect of exposure of the cells to low temperature. Indeed, shifting the temperature from 37°C or 40°C to 31°C allowed, within 1 h, the exit of tyrosinase from the ER, as seen by the accumulation of mature, Endo H-resistant glycoforms (Fig. 3 A-C) , confirming processing in the Golgi compartment (Fig. 3B) . Likewise, tyrosinase activity in all four melanoma cell lines had increased significantly (2-3-fold) after 4 h at the permissive temperature ( Fig. 3D and Inset) . For yet unknown reasons, a similar treatment of normal human melanocytes caused a slight, but nevertheless reproducible, decrease (35%) in tyrosinase activity (Fig. 3D) . The facilitated maturation of melanoma tyrosinase cannot be explained by temperature-induced changes in the expression of the chaperones listed above or in the binding capacity to calnexin and͞or calreticulin because no such changes were observed (data not shown). Our data imply that, in melanoma cells, the environment is altered and imparts temperature sensitivity preferentially to tyrosinase.
Accumulation of Tyrosinase Peptide in Response to
Protease Inhibitors. ER glycoproteins targeted for destruction are thought to be exported to the cytosol, where they are deglycosylated by an N-glycanase and digested further by proteasomal enzymes (43, 44) . For major histocompatibility complex class I molecules, degradation in response to cytomegalovirus is believed to involve the relocation of newly synthesized polypeptide chains from the ER to the cytosol by the Sec61 complex, the same complex responsible for insertion of glycoproteins into the ER membrane (44, 45 2, 4 , and 5) or control rabbit IgG (lanes 3 and 6) were Western blotted with anti-ubiquitin 4F3 mAb. After stripping, the same membrane was probed with anti-tyrosinase mAb (Ty'ase). Extracts were from normal melanocytes incubated for 4 h with DMSO (lanes 1 and 4) or LLnL (50 M, lanes 2, 3, 5, and 6). Arrowheads in B-E point at the 60-kDa doublet of tyrosinase. Arrows point at normal and melanoma tyrosinase glycoproteins.
It was compared with MG132 and lactacystin, both highly specific for proteasomes, and E64, a cysteine protease inhibitor that does not block proteasome activity (reviewed in 49), and ammonium chloride, an inactivator of lysosomal hydrolases.
Inhibitor-mediated protection against proteolytic degradation in melanocytes was first confirmed on a model protein, p21 WAF1͞Cip1 (50) . Indeed, the protease inhibitors enabled the accumulation of normal size p21 WAF1͞Cip1 . LLnL inhibited p21 WAF1͞Cip1 degradation in a time-and concentrationdependent manner (Fig. 4A, lanes 1-9) . Furthermore, LLnL, or lactacystin, but not E64, blocked the proteolysis of p21 WAF1͞Cip1 in both normal and malignant melanocytes (Fig. 4A, lanes  10-21) .
Similar analyses applied to tyrosinase showed that the proteasome inhibitors caused accumulation of a doublet protein of Ϸ60 kDa, which appeared more prominent in malignant than in normal melanocytes (Fig. 4 B and C) . Levels of the 60-kDa doublet in different cell lines correlated positively with the 70-kDa doublet rather than mature tyrosinase (Fig. 4 B and C) . The 60-kDa protein did not bind lectin (data not shown), and its molecular mass corresponded to the deglycosylated tyrosinase polypeptide; it migrated to the same position as N-glycosidase F-cleaved protein (Figs. 4D) . No accumulation of 60-kDa protein was observed with E64 (50 M for 4 h) or ammonium chloride (20 mM for 2 h) (data not shown). Appearance of unglycosylated tyrosinase peptide in response to proteasome inhibitors is consistent with tyrosinase being dislodged from the ER and deglycosylated by an N-glycanase before proteasomal degradation.
As expected from a protein that is not rapidly degraded, short term treatment with LLnL caused an Ϸ2-fold increase in the 70-80-kDa tyrosinase protein in normal melanocytes and slightly melanotic melanoma cells (Fig. 4B compare lane 1 to lanes 3 and 4; lane 16 to 17). An additional effect of LLnL was facilitation of tyrosinase processing in malignant cells, indicated by the appearance of Ϸ80-kDa molecular weight forms of tyrosinase (Fig. 4 B, compare lane 5 to lanes 6-8, lane 9 to 10-11, and lane 12 to 13-15, and C, compare lanes NA and LLnL) that were Endo H-resistant (data not shown). MG132 was less effective (Fig. 4C , melanomas 501 mel, YUSIT1, and YUGEN8), and lactacystin had an effect in only one experiment of three (Fig. 4C ). Extended incubation with LLnL (7 or 24 h) caused a general reduction in tyrosinase protein, precluding studies on long term effects (data not shown).
Proteasomal degradation of tyrosinase in normal melanocytes was confirmed by the ubiquitination of tyrosinase peptide in response to LLnL, as shown by immunoblotting of tyrosinase immunoprecipitates with anti-ubiquitin antibodies (Fig. 4D ). This approach revealed high molecular weight forms of ubiquitinated tyrosinase beyond the 199-kDa marker and a Ϸ58-kDa species present in LLnL-treated but not untreated melanocytes (Fig. 4D) . Ubiquitin was not associated with normal size tyrosinase (Fig. 4D, lanes 2 and 3) .
To further confirm that inhibition of tyrosinase degradation facilitated maturation, the effect of LLnL was explored by pulse-chase and by examining chaperone binding and subcellular localization. First, in pulse-chase experiments, LLnL had no effect on tyrosinase maturation in normal melanocytes (Fig. 5A , compare lane 3 to 6) but enhanced processing of newly synthesized protein in two amelanotic melanoma cell lines (501 mel, Fig.  5A , compare lane 17 to 21 and YUSIT1; also data not shown) and the slightly melanotic melanoma line (YUGEN8) (Fig. 5A,  compare lane 9 to 12) . Second, association of tyrosinase with calreticulin was greatly enhanced after 4 h of treatment of melanoma cells with LLnL (Fig. 5B, compare to 8). Lines 501mel and YUGEN8, which, in the amelanotic state, did not bind calreticulin (Fig. 2C, lanes 7 and 10) , did so when they became slightly pigmented (Fig. 5B, lanes 3, 4 and 9 , 10, respectively). Third, electron micrographs revealed only sparse dopa reaction product in untreated amelanotic melanoma cells but ample activity after exposure to LLnL (Fig. 5C, compare a to b) . Activity was localized to trans-Golgi cisternae and tubulovesicular network and in premelanosomes (Fig. 5Cc) . Although the dopa reaction is not amenable to precise quantification, our findings suggest an increased translocation of tyrosinase in response to LLnL. No such increase was observed with lactacystin (data not shown).
Incubation of cells with E64 or ammonium chloride did not affect intracellular degradation or production of 80-kDa forms of tyrosinase, suggesting that the protein was not degraded in acidic compartments such as lysosomes, trans-Golgi elements, endosomes, or melanosomes (data not shown).
The prevalence in melanomas of the 70-kDa immature form associated with calnexin was highly selective for tyrosinase; it was not seen with other melanocyte-specific glycoproteins, such as gp75 or TRP2 (data not shown). This substrate specificity is perhaps due to environmentally induced changes that delay maturation of a protein that is processed relatively slowly even in normal melanocytes. The highly homologous gp75, whose sequence also predicts five glycosylation sites, is processed within 2 h in the human melanoma cell line SK-MEL-19 (51) compared with over 6 h for tyrosinase in normal melanocytes. The block in tyrosinase processing is unlikely to arise from a common mutation in the eight melanoma cell lines we have studied (chosen randomly from lines established from patients, and not all are illustrated here). Sequence analyses of tyrosinase cDNA from melanoma cell line YUSAC2 did not reveal any mutation (data not shown), and others have reported normal tyrosinase cDNA sequence in a melanoma cell line (52) . Furthermore, the finding that, in another melanoma cell line, 20% of tyrosinase appears as a 53-kDa soluble form (53) suggests that accelerated degradation is not particular to our cell lines. Our observation that LLnL not only prevented degradation but also enhanced maturation of tyrosinase may signify that inhibition of peptidases other than in proteasomes, possibly in the ER (54) , tips the balance toward processing.
In summary, proteasome inhibitors induced the accumulation of 60-kDa tyrosinase protein, indicating that, in the absence of such inhibitors, a portion of newly synthesized tyrosinase is diverted from the ER into degradation by the proteasome complex, a process that does occur in normal melanocytes but is accelerated in melanoma cells. These observations may explain the existence of T cell clones reactive against tyrosinase peptides in normal individuals as well as in melanoma patients (see, for example, ref. 55).
